Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.

Next Previous
Trial Profile

Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Glimepiride; Rosiglitazone
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms LEAD-1
  • Sponsors Novo Nordisk

Most Recent Events

  • 09 Jul 2012 Additional trial location (New Zealand) added as reported by ClinicalTrials.gov.
  • 25 Jun 2010 Outcomes from a pooled anlaysis of the 6 LEAD trials were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
  • 25 Jan 2010 Novo Nordisk's Victoza(R) received FDA Approval for Adults With Type 2 Diabetes based on results of LEAD phase III trial programme, according to a Novo Nordisk media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top